MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 591440 | Name: AH-1058 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AH-1058 HCl is a lipophilic antiarrhythmic calcium channel blocker. It is derived from cyproheptadine, a compound with known antiserotonic, antihistaminic and calcium channel blocking properties.

Chemical Structure

AH-1058 HCl
AH-1058 HCl
CAS#228123-15-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 591440

Name: AH-1058 HCl

CAS#: 228123-15-7 (HCl)

Chemical Formula: C30H29ClN2O3

Exact Mass: 500.1867

Molecular Weight: 501.02

Elemental Analysis: C, 71.92; H, 5.83; Cl, 7.08; N, 5.59; O, 9.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
300347-11-9 (free base) 228123-15-7 (HCl)
Synonym
AH-1058 HCl; AH 1058 HCl; AH1058 HCl; AH-1058 hydrochloride;
IUPAC/Chemical Name
Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-((2E)-3-(3-methoxy-2-nitrophenyl)-2-propen-1-yl)-, hydrochloride (1:1)
InChi Key
HUGNVHKJRQLOAZ-RVDQCCQOSA-N
InChi Code
InChI=1S/C30H28N2O3.ClH/c1-35-28-14-6-10-25(30(28)32(33)34)11-7-19-31-20-17-24(18-21-31)29-26-12-4-2-8-22(26)15-16-23-9-3-5-13-27(23)29;/h2-16H,17-21H2,1H3;1H/b11-7+;
SMILES Code
O=[N+](C1=C(OC)C=CC=C1/C=C/CN2CC/C(CC2)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35)[O-].[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 501.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dohmoto H, Takahara A, Uneyama H, Yoshimoto R. Cardiac Ca(2+) channel-blocking effects of the cyproheptadine derivative AH-1058 in isolated guinea pig cardiomyocytes. J Pharmacol Sci. 2003 Feb;91(2):163-6. PubMed PMID: 12686762. 2: Takahara A, Sugiyama A, Yoshimoto R, Hashimoto K. AH-1058: a novel cardioselective Ca2+ channel blocker. Cardiovasc Drug Rev. 2001 Winter;19(4):279-96. Review. PubMed PMID: 11830748. 3: Takahara A, Hirasawa A, Dohmoto H, Shoji M, Yoshimoto R, Sugiyama A, Hashimoto K. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models. Jpn J Pharmacol. 2001 Sep;87(1):21-6. PubMed PMID: 11676194. 4: Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Utilization of telemetry system to assess the cardiovascular profile of AH-1058, a new cardioselective Ca2+ channel blocker, in conscious dogs. Jpn J Pharmacol. 2001 Mar;85(3):331-4. PubMed PMID: 11325028. 5: Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Cardiovascular action of a cardioselective Ca(2+)channel blocker AH-1058 in conscious dogs assessed by telemetry. Eur J Pharmacol. 2001 Feb 9;413(1):101-8. PubMed PMID: 11173068. 6: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model. Jpn J Pharmacol. 2000 Jun;83(2):107-12. PubMed PMID: 10928322. 7: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models. Eur J Pharmacol. 2000 Jun 9;398(1):107-12. PubMed PMID: 10856454. 8: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Comparison of cardiovascular effects of a new calcium channel blocker AH-1058 with those of verapamil assessed in blood-perfused canine heart preparations. J Cardiovasc Pharmacol. 2000 May;35(5):741-8. PubMed PMID: 10813376. 9: Tanaka H, Ichikawa T, Matsui S, Okazaki K, Masumiya H, Kawanishi T, Shigenobu K. Calcium channel antagonistic effects of AH-1058, a novel antiarrhythmic drug, on guinea-pig myocardium. Res Commun Mol Pathol Pharmacol. 1999;104(1):13-21. PubMed PMID: 10604274. 10: Takahara A, Uneyama H, Sasaki N, Ueda H, Dohmoto H, Shoji M, Hara Y, Nakaya H, Yoshimoto R. Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents. J Cardiovasc Pharmacol. 1999 Apr;33(4):625-32. PubMed PMID: 10218734.